N-acetyl cysteine: A tool to perturb SARS-CoV-2 spike protein conformation
The infection caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) resulted in a pandemic with huge death toll and economic consequences. The virus attaches itself to the human epithelial cells through noncovalent bonding of its spike protein with the angiotensin-converting enzyme-2 (ACE2) receptor on the host cell. We hypothesized that perturbing the functionally active conformation of spike protein through reduction of its solvent accessible disulfide bond, thereby disintegrating its structural architecture, may be a feasible strategy to prevent infection. Proteomics data showed that N-acetyl cysteine (NAC), an antioxidant and mucolytic agent been widely in use in clinical medicine, forms covalent conjugates with solvent accessible cysteine residues of spike protein that were disulfide bonded in the native state. In silico analysis indicated that this covalent conjugation perturbed the stereo specific orientations of the interacting key residues of spike protein that resulted in threefold weakening in the binding affinity of spike protein with ACE2 receptor. Antiviral assay using VeroE6 cells showed that NAC caused 54.3% inhibition in SARS-CoV-2 replication. Interestingly, almost all SARS-Cov-2 variants conserved cystine residues in the spike protein. Our observed results open avenues for exploring in vivo pharmaco-preventive and therapeutic potential of NAC for Coronavirus Disease 2019 (COVID-19)..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
chemRxiv.org - (2021) vom: 18. Nov. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Debnath, Utsab [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.26434/chemrxiv.12687923 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XCH018395252 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XCH018395252 | ||
| 003 | DE-627 | ||
| 005 | 20230429142640.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200723s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.26434/chemrxiv.12687923 |2 doi | |
| 035 | |a (DE-627)XCH018395252 | ||
| 035 | |a (chemrXiv)10.26434/chemrxiv.12687923 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Debnath, Utsab |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a N-acetyl cysteine: A tool to perturb SARS-CoV-2 spike protein conformation |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a The infection caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) resulted in a pandemic with huge death toll and economic consequences. The virus attaches itself to the human epithelial cells through noncovalent bonding of its spike protein with the angiotensin-converting enzyme-2 (ACE2) receptor on the host cell. We hypothesized that perturbing the functionally active conformation of spike protein through reduction of its solvent accessible disulfide bond, thereby disintegrating its structural architecture, may be a feasible strategy to prevent infection. Proteomics data showed that N-acetyl cysteine (NAC), an antioxidant and mucolytic agent been widely in use in clinical medicine, forms covalent conjugates with solvent accessible cysteine residues of spike protein that were disulfide bonded in the native state. In silico analysis indicated that this covalent conjugation perturbed the stereo specific orientations of the interacting key residues of spike protein that resulted in threefold weakening in the binding affinity of spike protein with ACE2 receptor. Antiviral assay using VeroE6 cells showed that NAC caused 54.3% inhibition in SARS-CoV-2 replication. Interestingly, almost all SARS-Cov-2 variants conserved cystine residues in the spike protein. Our observed results open avenues for exploring in vivo pharmaco-preventive and therapeutic potential of NAC for Coronavirus Disease 2019 (COVID-19). | ||
| 650 | 4 | |a Chemistry |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 540 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Mitra, Amrita |e verfasserin |4 aut | |
| 700 | 1 | |a Dewaker, Varun |e verfasserin |4 aut | |
| 700 | 1 | |a Prabhakar, Yenamandra S. |e verfasserin |4 aut | |
| 700 | 1 | |a Tadala, Raghu |e verfasserin |4 aut | |
| 700 | 1 | |a Krishnan, Kiran |e verfasserin |4 aut | |
| 700 | 1 | |a Wagh, Padmakar |e verfasserin |4 aut | |
| 700 | 1 | |a Velusamy, Umashankar |e verfasserin |4 aut | |
| 700 | 1 | |a Subramani, Chandru |e verfasserin |4 aut | |
| 700 | 1 | |a Agarwal, Shubhra |e verfasserin |4 aut | |
| 700 | 1 | |a Vrati, Sudhanshu |e verfasserin |4 aut | |
| 700 | 1 | |a Baliyan, Aastha |e verfasserin |4 aut | |
| 700 | 1 | |a Kurpad, Anura V |e verfasserin |4 aut | |
| 700 | 1 | |a Bhattacharyya, Parthasarathi |e verfasserin |4 aut | |
| 700 | 1 | |a Mandal, Amit |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t chemRxiv.org |g (2021) vom: 18. Nov. |
| 773 | 1 | 8 | |g year:2021 |g day:18 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.26434/chemrxiv.12687923 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XCH | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 18 |c 11 | ||